CRISPR Therapeutics AG (CRSP): Price and Financial Metrics
GET POWR RATINGS... FREE!
CRSP POWR Grades
- Growth is the dimension where CRSP ranks best; there it ranks ahead of 91.34% of US stocks.
- The strongest trend for CRSP is in Momentum, which has been heading down over the past 206 days.
- CRSP's current lowest rank is in the Momentum metric (where it is better than 5.09% of US stocks).
CRSP Stock Summary
- With a price/sales ratio of 6,950.65, CRISPR Therapeutics AG has a higher such ratio than 99.75% of stocks in our set.
- Over the past twelve months, CRSP has reported earnings growth of -945.58%, putting it ahead of only 1.69% of US stocks in our set.
- Revenue growth over the past 12 months for CRISPR Therapeutics AG comes in at -99.62%, a number that bests only 0.63% of the US stocks we're tracking.
- If you're looking for stocks that are quantitatively similar to CRISPR Therapeutics AG, a group of peers worth examining would be PLXP, ETON, TGTX, VHC, and VNRX.
- CRSP's SEC filings can be seen here. And to visit CRISPR Therapeutics AG's official web site, go to www.crisprtx.com.
CRSP Price Target
For more insight on analysts targets of CRSP, see our CRSP price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $157.12 | Average Broker Recommendation | 1.65 (Moderate Buy) |
CRSP Stock Price Chart Interactive Chart >
CRSP Price/Volume Stats
| Current price | $106.64 | 52-week high | $220.20 |
| Prev. close | $101.00 | 52-week low | $54.86 |
| Day low | $101.82 | Volume | 1,424,700 |
| Day high | $108.42 | Avg. volume | 2,071,877 |
| 50-day MA | $120.42 | Dividend yield | N/A |
| 200-day MA | $121.71 | Market Cap | 8.08B |
CRISPR Therapeutics AG (CRSP) Company Bio
CRISPR Therapeutics AG focuses on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. The company is based in Basel, Switzerland.
Latest CRSP News From Around the Web
Below are the latest news stories about CRISPR Therapeutics AG that investors may wish to consider to help them evaluate CRSP as an investment opportunity.
Vertex: While The Market Remains Indifferent, Now Is The Time To CommitPhoto by sanjeri/E+ via Getty Images Vertex Pharmaceuticals (VRTX) recently reported first-quarter numbers that surpassed market expectations. The company has established itself as the dominant force in cystic fibrosis ((CF)) treatment and is building an impressive pipeline. Although the share price has remained suppressed, the company is making all the... |
CRISPR upgraded to outperform at Evercore as leader in gene editingEvercore ISI has upgraded shares of CRISPR Therapeutics (CRSP) to outperform as it could be the first company to have a gene editing product approved.Analyst Liisa Bayko notes that the company will release data on all four of its clinical stage assets.She says that the Vertex-partnered CTX001, a therapy in... |
Vertex and CRISPR Therapeutics to Present New Clinical Data on Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001™ For Severe Hemoglobinopathies at the Annual European Hematology Association Virtual CongressCAMBRIDGE, Mass. and ZUG, Switzerland and BOSTON, May 12, 2021 (GLOBE NEWSWIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced two abstracts detailing updated data from the ongoing CTX001 clinical trials have been accepted for presentation during the European Hematology Association (EHA) 2021 Virtual Congress. Abstract #EP736 entitled “CTX001 for Sickle Cell Disease: Safety and Efficacy Results from the Ongoing CLIMB SCD-121 Study of Autologous Crispr-Cas9-Modified CD34+ Hematopoietic Stem and Progenitor Cells,” will be made available on the virtual platform as an e-poster Friday, June 11 at 9:00 CEST. The abstract posted online today includes data on patients with severe sickle cell disease with more than 3 months of follow-... |
3 Healthcare Stocks That Might Soar if Biden Gets This Part of His Budget ApprovedOne of the most notable items in Joe Biden's recent budget proposal is $6.5 billion to create an agency called the Advanced Research Projects Agency for Health, or ARPA-H. The naming is intended to mirror DARPA, the defense agency that had a hand in producing the internet, GPS, and Boston Dynamics robots like this. The goal of the agency would be to lead the charge in curing cancer, Alzheimer's, and diabetes. If the agency is created, that could send funding toward cutting-edge diabetes research from companies like CRISPR Therapeutics (NASDAQ: CRSP) and Vertex Pharmaceuticals (NASDAQ: VRTX), as well as those helping better manage the disease like Teladoc's (NYSE: TDOC) Livongo unit. |
Nkarta, CRISPR Join Forces On CAR-NK Development For CancerNkarta Inc (NASDAQ: NKTX ) has collaborated with CRISPR Therapeutics AG (NASDAQ: CRSP ) to co-develop and commercialize two CAR-NK therapies, in addition to an NK+T program. The companies will split all the R&D costs and any worldwide … Full story available on Benzinga.com |
CRSP Price Returns
| 1-mo | -10.05% |
| 3-mo | -31.34% |
| 6-mo | -0.10% |
| 1-year | 74.56% |
| 3-year | 64.87% |
| 5-year | N/A |
| YTD | -30.35% |
| 2020 | 151.39% |
| 2019 | 113.18% |
| 2018 | 21.68% |
| 2017 | 15.89% |
| 2016 | N/A |
Continue Researching CRSP
Here are a few links from around the web to help you further your research on CRISPR Therapeutics AG's stock as an investment opportunity:CRISPR Therapeutics AG (CRSP) Stock Price | Nasdaq
CRISPR Therapeutics AG (CRSP) Stock Quote, History and News - Yahoo Finance
CRISPR Therapeutics AG (CRSP) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...